» Articles » PMID: 29471502

Elevated G6PD Expression Contributes to Migration and Invasion of Hepatocellular Carcinoma Cells by Inducing Epithelial-mesenchymal Transition

Overview
Specialties Biochemistry
Biophysics
Date 2018 Feb 23
PMID 29471502
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Altered metabolism is one of the hallmarks of cancer cells. Pentose phosphate pathway (PPP) is a fundamental component of cellular metabolism. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, is elevated in many cancers and contributes to tumor growth by producing ribose-5-phosphate and NADPH through PPP. However, the role of G6PD in hepatocellular carcinoma (HCC) metastasis and the clinical significance of G6PD in HCC progression and prognosis have not been well determined. In this study, by investigating tissue samples from HCC patients and HCC cell lines, we found that elevated G6PD expression is significantly associated with HCC metastasis and poor prognosis of HCCs, and that knockdown of G6PD inhibits in vitro proliferation, migration and invasion of HCC cell lines. Further studies reveal that G6PD contributes to HCC migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition through activation of signal transducer and activator of transcription 3 (STAT3) pathway. Our findings suggest that targeting G6PD could open up possibilities for metastasis intervention and improve the patients' outcomes for HCC.

Citing Articles

The collagen-modifying enzyme GLT25D1 is a prognostic indicator related to immunosuppression and malignant phenotypes in hepatocellular carcinoma.

Qiu S, Han H, Zhang H, Yang M, Wang H, Li K Cancer Cell Int. 2025; 25(1):84.

PMID: 40057713 PMC: 11889767. DOI: 10.1186/s12935-025-03715-z.


Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications.

Park S, Hall M Exp Mol Med. 2025; .

PMID: 40025169 DOI: 10.1038/s12276-025-01415-2.


Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.

Wang K, Li X, Guo S, Chen J, Lv Y, Guo Z Front Oncol. 2025; 15:1545086.

PMID: 39980550 PMC: 11839411. DOI: 10.3389/fonc.2025.1545086.


Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.

Ruan L, Fang N, Zhao X, Chen W, Wu Z, Wu X Discov Oncol. 2025; 16(1):116.

PMID: 39903352 PMC: 11794919. DOI: 10.1007/s12672-025-01851-6.


The Pentose Phosphate Pathway: From Mechanisms to Implications for Gastrointestinal Cancers.

Qiao J, Yu Z, Zhou H, Wang W, Wu H, Ye J Int J Mol Sci. 2025; 26(2).

PMID: 39859324 PMC: 11765532. DOI: 10.3390/ijms26020610.